ArticleHeliyon2025
Integrated and streamlined microfluidic device for molecular diagnosis of pathogen through direct PCR amplification.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polymerase chain reaction (PCR) is a gold-standard method widely acknowledged for offering precise and rapid analysis of genetic material, particularly having a crucial role in detecting pathogens and diagnosing infectious diseases. However, the complexity of the PCR process (including nucleic acid extraction/purification, amplification, and amplicon detection) hinders its widespread adoption in point-of-care testing, where simplicity and rapidity are essential for practical use. Results: In this study, we developed a microfluidic genetic analysis device that leverages direct PCR technology to simplify the entire PCR process, focusing on enhancing the usability and accessibility of the device for point-of-care diagnostics. Direct PCR, which enables direct DNA amplification from biological samples without the need for DNA extraction and purification, streamlines the device architecture and transforms it into a more user-friendly form. Within the device, two spatially separated zones for PCR and micro-capillary electrophoresis (μCE) are sequentially connected via a microchamber plate, which is slidable on top of the device and transfers the amplified products from the PCR zone to the μCE zone for subsequent analysis. Using our device, we quantitatively analyzed two types of bacteria- Significance: Considering how prominent PCR is for diagnostics, this work represents the potential to make traditionally labor-intensive molecular assays available in a decentralized point-of-care setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.